Thrombosis

Research Article

Urinary Prothrombin Fragment 1+2 in relation to Development of Non-Symptomatic and Symptomatic Venous Thromboembolic Events following Total Knee Replacement

Table 2

Levels of prothrombin fragment 1+2 in urine in relation to treatment regimen. Lower limit of detection 20 pmol/L, upper limit 1,200 pmol/L. bid: twice daily; uF1+2: prothrombin fragment 1+2 in urine; VTE: venous thromboembolism.
Level of uF1+2, pmol/L, median (range)RivaroxabanEnoxaparin
2.5 mg bid5 mg bid10 mg bid20 mg bid30 mg bid30 mg bid
Cases ( 𝑛 = 2 2 )Controls ( 𝑛 = 1 7 )Cases ( 𝑛 = 2 5 )Controls ( 𝑛 = 2 1 )Cases ( 𝑛 = 1 6 )Controls ( 𝑛 = 3 2 )Cases ( 𝑛 = 2 2 )Controls ( 𝑛 = 2 3 )Cases ( 𝑛 = 1 5 )Controls ( 𝑛 = 2 4 )Cases ( 𝑛 = 3 0 )Controls ( 𝑛 = 1 7 )
Preoperative20 (<20–136.5)27.1 (<20–287.3)20.5 (20–414.8)20 (<20–32.8)20 (<20–1,025)23 (<20–457.5)20.1 (<20–68.1)20 (<20–431.2)25.6 (<20–323)20 (<20–127.3)20 (<20–212.6)27.9 (<20–190.8)
Day of venography31.3 (<20–475.7)29.5 (<20–542)82.2 (<20–869.1)24.9 (<20–470.4)35.5 (<20–780.9)31.8 (<20–660.2)43.6 (<20–702.5)31 (<20–461.5)50.2 (<20–501.2)23.3 (<20–212.6)31.4 (<20–852)44.6 (<20–243.7)
Day of follow-up22.2 (<20–74.3)23.9 (<20–117.4)22.1 (<20–258.3)20 (<20–831.8)23.1 (<20–>1,200)20 (<20–269.9)25.9 (<20–460.2)20.9 (<20–80.6)24 (<20–152.7)20.9 (<20–113.5)20 (<20–192.9)24.3 (<20–161.7)